Discover trends, market shifts, and competitive outlooks for the in vitro diagnostic (ivd) in cardiology and neurology industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Milestones in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market’s Growth Trajectory From 2025 To 2034?
The cardiology and neurology segments of the in vitro diagnostic (IVD) market have seen robust growth in recent years. From 2024’s $15.84 billion, the market is predicted to reach $17.27 billion in 2025, marking an impressive compound annual growth rate (CAGR) of 9.0%. The increase in the past period can be traced back to several factors. These include a higher incidence of age-related cardiovascular and neurological conditions, a rise in the aging population, a growing focus on early disease detection and preventive healthcare, a greater incidence of cardiovascular diseases (CVDs) like stroke and Alzheimer’s disease, higher investment in healthcare infrastructure, as well as supportive regulatory environments that facilitate the approval and reimbursement of diagnostic tests.
The market size for in vitro diagnostic (IVD) within the fields of cardiology and neurology is projected to experience robust growth in the coming years, with values expected to reach $24.07 billion by 2029 at a compounded annual growth rate of 8.7%. This expected market growth during the forecast period can be credited to a myriad of factors including a shift toward personalised medicine within cardiology and neurology, a mounting demand for faster on-site testing solutions, the rise of telemedicine and virtual consultation services, as well as an increase in research imperatives. The upcoming trends for the forecast period revolve around the emergence of liquid biopsy technologies, breakthroughs in nanotechnology, increasing use of remote monitoring gadgets like implantable cardiac monitors and brain-computer interfaces, the employment of multiplex biomarker panels, innovative strides in medical imaging modalities, like MRI, CT, and PET scans, and the formulation of companion diagnostics for cardiovascular and neurological drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
The in vitro diagnostic (IVD) market for cardiology and neurology is poised for significant growth, propelled by the burgeoning field of personalized medicine. Personalized medicine customizes healthcare decisions, practices, procedures, and treatments to fit the individual patient’s unique characteristics. It is a field seeing rapid growth due to advancements in genomics, a better understanding of how diseases work, patients demanding treatments customized for them, and backing from regulatory bodies, among other factors. IVD tests play a key role in personalized medicine within cardiology and neurology by providing critical data on a person’s genetic configuration and disease state, which assists in formulating custom treatment plans for better results and fewer risks. To illustrate, the Personalized Medicine Coalition, a professional organization based in the U.S, stated that in 2022, around 34% of all newly approved therapies, equating to 12 new personalized medicines, indicated a marked increase from previous years. Thus, the surge in personalized medicines is stimulating the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.
Which Primary Segments of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Are Driving Growth and Industry Transformations?
The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp
What Are the Fastest-Growing Geographies in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry Evolution?
Key players in the cardiologic and neurologic segments of the in vitro diagnostic (IVD) marketplace are advancing AI-integrated epigenetics mechanisms, specifically designed to detect diseases earlier and accurately assess risks. These cutting-edge engines employ machine learning algorithms and sophisticated biomarker analysis methodologies to increase precision and sensitivity in diagnosing and monitoring heart diseases, addressing significant factors instigating disease development. In particular, Cardio Diagnostics Holdings Inc., an American biotech firm, introduced an AI-powered blood test named PrecisionCHD in February 2023. This test was developed for early identification of coronary heart disease (CHD) and relied on the company’s holistic epigenetic-genetic engine to gauge CHD risk with the intention to preempt and pinpoint the most frequent type of cardiovascular ailment. By amalgamating epigenetic and genetic biomarkers with machine learning models, this new test ensures above 75% accuracy for both genders. It connects a patient’s biomarker tendency with alterable risk elements, which are primary triggers for CHD such as smoking, diabetes, hypertension, and heightened cholesterol levels. The PrecisionCHD presents a non-intrusive option as opposed to angiograms or exercise stress tests, whilst blood samples can be collected at the comfort of patients’ homes or in clinics.
View the full report here:
What Parameters Are Used to Define the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?
In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer’s disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
